Role of Nk Cells and Non-nk Ilcs in Disease Progression and Their Application as Targets for Immune Interventions
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cellular/Molecular Immunology".
Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 3570
Special Issue Editor
Special Issue Information
Dear Colleagues,
The new emerging insights into NK cell biology (e.g. adaptive immune features) in the last decades as well as the discovery of novel ILC subsets advocate them as potential targets to combat infectious diseases. Although the impact of NK cells and non-NK ILCs on the generation of adaptive immune responses has been described, they are still largely neglected concerning their impact on the establishment of new immune interventions aimed at preventing or treating infectious diseases. However, their described double-edged role in the course of infections requires special attention to define their range of application. We are therefore happy to announce a vaccines special issue dealing with the role of NK cells and non-NK ILCs in the context of infectious diseases with a special focus on their impact for the establishment of prophylactic or therapeutic immune interventions. We encourage the presentation of new findings and advances in this field of research that will contribute to the advancement of inventive modern medical approaches. These findings might encompass host-pathogen interactions or mechanisms of action in the context of murine infection or immunization studies as well as applied research and clinical studies.
Dr. Peggy Riese
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NK cells
- Non-NK ILCs
- Infectious Diseases
- Immune Interventions
- Inflammation
- Immune regulation Plasticity
- Murine infection models
- Clinical research studies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.